• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Jenna Earl

Article

Jenna Ealr is Senior Consultant at Blue Latitude

http://bluelatitude.net/about-us-strategic-marketing-consultants/jenna/

Related Videos
Related Content
Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more

Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more

April 26th 2024
Article

The latest news for pharma industry insiders.

Fierce Females in the Life Science Space

Fierce Females in the Life Science Space

March 29th 2024
Podcast

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Mark Melton

Solving the First Mile Problem: Q&A with Mark Melton

April 26th 2024
Article

Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.

Gen-Z Influence on Pharma M&A

Gen-Z Influence on Pharma M&A

March 14th 2024
Podcast

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Novartis, Medicines for Malaria Venture Release Positive Results from Phase II/III Trial of Coartem for Infants with Malaria

Novartis, Medicines for Malaria Venture Release Positive Results from Phase II/III Trial of Coartem for Infants with Malaria

April 25th 2024
Article

Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.

FDA Approves Utility Therapeutics’ Pivya to Treat Uncomplicated Urinary Tract Infections in Adult Females

FDA Approves Utility Therapeutics’ Pivya to Treat Uncomplicated Urinary Tract Infections in Adult Females

April 25th 2024
Article

Pivya has shown efficacy against bacteria strains such as Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.